Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7175455

O=C(Pc1ccc(OCc2ccccc2)cc1OCc1ccccc1)c1c(Cl)cccc1Cl.[Li]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MITF O75030 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ XBP1 P17861 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ NFKB2 Q00653 1/20 0.46
▸ RELA Q04206 1/20 0.46
▸ MAOB P27338 4/20 0.46
▸ RXRA P19793 2/20 0.46
▸ RXRB P28702 2/20 0.46
▸ MRGPRX4 Q96LA9 5/20 0.45
▸ FFAR1 O14842 2/20 0.45
▸ NR4A2 P43354 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ RXRG P48443 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175449 0.98 HPGD (0.46) HPGDMEN1NPC1RAB9AKMT2A
Lithium SCHEMBL7175251 0.94 MRGPRX4 (0.44) HPGDMEN1NPC1RAB9AKMT2A
Lithium SCHEMBL7177464 0.94 MRGPRX4 (0.46) HPGDMEN1NPC1RAB9AKMT2A
SCHEMBL7177460 0.91 MRGPRX4 (0.46) HPGDMEN1NPC1RAB9AKMT2A
SCHEMBL7175247 0.91 L3MBTL1 (0.46) HPGDMEN1NPC1RAB9AKMT2A
Lithium SCHEMBL7177776 0.87 MAOB (0.48) MAOBRXRARXRBFFAR1NR4A2
Lithium SCHEMBL7187439 0.86 MRGPRX4 (0.47) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL7179313 0.85 MRGPRX4 (0.53) MAOBRXRARXRBMRGPRX4FFAR1
SCHEMBL7177769 0.85 MAOB (0.48) MAOBRXRARXRBFFAR1NR4A2
Lithium SCHEMBL7182438 0.84 MRGPRX4 (0.48) MAOBRXRARXRBMRGPRX4FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 HPGD 3983/4885MEN1 2312/4885NPC1 772/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 HPGD 4041/4885MEN1 2263/4885NPC1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.